Polymerized Type I Collagen Reverts Airway Hyperresponsiveness and Fibrosis in a Guinea Pig Asthma Model by Blanca Bazán-Perkins et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
15 
Polymerized Type I Collagen Reverts Airway 
Hyperresponsiveness and Fibrosis 
in a Guinea Pig Asthma Model 
Blanca Bazán-Perkins1, Maria G. Campos2 
and Edgar Sánchez-Guerrero1 
1Instituto Nacional de Enfermedades Respiratorias, 
 2Instituto Mexicano del Seguro Social, 
México 
1. Introduction 
Asthma is a chronic, heterogeneous and variable disease in which airways inflammation, 
transient obstruction and hyperresponsiveness are the major features of the illness (Faffe, 
2008; Jenkins et al., 2005; Lemanske & Busse, 2010; Sugita et al., 2003). The inflammation in 
asthma is characterized by eosinophil cell infiltration although neutrophils are also observed 
in acute asthma exacerbation and in severe asthma patients (Fahy, 2009; Kim & Rhee, 2010; 
Venge, 2010). A main role of eosinophils and neutrophils in asthma is to release mediators 
involved in the development of airway pathological structural changes, the called airway 
remodeling. An important consequence of airway remodeling is the thickening of the 
airway wall produced by the deposit of extracellular matrix components (Bazan-Perkins et 
al., 2009; Janson, 2010; Salerno et al., 2009). The enlargement of airway wall could alter the 
transient airway obstruction in asthma that usually is resolved either spontaneously or after 
treatment, by inducing a residual and permanent airway obstruction (Broekema et al., 2011; 
Janson, 2010; Jeffery et al., 2000; Wenzel, 2003).  
Airway hyperresponsiveness is a crucial physiopathological feature of asthma fundamentally 
because maintains a relation to the disease magnitude (Busse, 2010; Cockcroft & Davis, 2006; 
O'Byrne & Inman, 2003; Sugita et al., 2003). Although the mechanism involved in the 
generation of airway hyperresponsiveness is not attributable to a single but to multiple 
pathological processes, two main factors could contribute to its development: inflammation 
and remodeling. In this scenario, it has been observed that the inflammatory factor is 
associated to inducible, transient and variable hyperresponsiveness while remodeling has been 
related to persistent airway hyperresponsiveness (Busse, 2010; Cockcroft & Davis, 2006; 
O'Byrne & Inman, 2003). Additionally, variable hyperresponsiveness occurs mainly in acute 
asthma while persistent hyperresponsiveness predominantly takes place in chronic or severe 
asthma (Cockcroft & Davis, 2006; O'Byrne & Inman, 2003; Wenzel, 2003). Nevertheless, 
independently of its pathological basis, the development of therapeutic strategies reducing the 
hyperresponsiveness is fundamental in asthma control. 
Polymerized type I collagen (PtI-collagen) is a composite made with a ┛-irradiated mixture 
of atelopeptidic porcine type I dermal collagen and polyvinylpyrrolidone that has shown 
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anti-inflammatory and fibrolytic properties in many diseases. In humans, PtI-collagen is 
safe, well-tolerated and non-genotoxic, as shown in short and long administration periods 
(Furuzawa-Carballeda et al., 2003). PtI-collagen effects has been evaluated in rheumatoid 
arthritis patients (Furuzawa-Carballeda et al., 1999; Furuzawa-Carballeda et al., 2003; 
Furuzawa-Carballeda et al., 2006; Furuzawa-Carballeda et al., 2002), skin diseases as 
scleroderma (Furuzawa-Carballeda et al., 2005), pressure ulcers (Zeron et al., 2007) and 
hypertrophic scars (Krotzsch-Gomez et al., 1998), and a case of its use in ileocolonic ulcer 
has also been reported (De Hoyos Garza et al., 2007).  
In bone fracture in rats, PtI-collagen stimulates the healing process and accelerates the new 
bone formation (Chimal-Monroy et al., 1998; Furuzawa-Carballeda et al., 2003). 
Furthermore, in neoformed bone tissue in dogs, favored the vascular growth and the 
expression of transforming growth factor-┚1 (Ascencio et al., 2004). After appendectomy in 
rabbits, decreases the incidence and size of intra-abdominal adhesions (Cervantes-Sanchez 
et al., 2003). Moreover, in the tracheoplasty site in dogs, reduces the inflammatory 
lymphocytic infiltration and the degree of fibrosis and tracheal stenosis (Olmos-Zuniga et 
al., 2007). In addition, in rat chronic cyclosporine nephropathy model, PtI-collagen has 
shown anti-apoptotic properties (Sanchez-Pozos et al., 2010).  
In guinea pigs we have observed that PtI-collagen administrated in acute asthma model 
reduces the expression of TNF in addition to airway eosinophil and neutrophil infiltration, 
as well as fibrosis (Moreno-Alvarez et al., 2010). In this study we have evaluated the effects 
of PtI-collagen in a guinea pig allergic-asthma model with remodeled airways and antigen-
induced airway hyperresponsiveness (AI-AHR) to histamine. 
2. Materials and methods 
We used healthy male guinea pigs (350-400 g) purchased originally from Harlan Mexico 
(strain HsdPoc:DH) and reproduced at our institutional laboratory animal facilities. Animals 
were bred in filtered air-conditioned, 12/12-h light/dark cycles, at 21±1°C and 50-70% 
humidity, and fed with sterilized pellets (2040 Harlan Teklad Guinea Pig Diet) and water ad 
libitum. The protocol was reviewed and approved by the Scientific and Bioethics 
Committees of the Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas 
in Mexico City. 
2.1 Study design 
After an initial sensitization protocol, guinea pigs were intermittently exposed to the 
aerosolized allergen (ovalbumin, OVA) for up to 125 days (asthma model group), receiving 
a total of twelve allergenic challenges (Fig. 1). The control group animals received saline 
solution instead OVA. Some animals from both asthma model and control groups were 
treated with 0.66 mg/ml of PtI-collagen aerosols administrated every 5 days from day 65 to 
day 120. The development of AI-AHR was evaluated in every guinea pig group by 
performing dose-response curves to histamine before and after either the antigen or saline in 
the reinforcement day (day 8) and at the sixth and twelfth antigenic or saline challenges. 
After the twelfth antigenic or saline challenges, animals were euthanized and a 
bronchoalveolar lavage was carried out to analyze cell count. Then, lung samples were 
obtained to analyze both the changes in the amount of collagen stain in subepithelial 
mucosa by Masson trichrome by light microscopy. Airway subepithelial mucosa was 
defined as the area comprised between the basal edge of epithelial cells and the beginning of 
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airway smooth muscle, a region containing mainly basement membrane and lamina 
propria. 
2.2 Sensitization procedure 
On the first day, each guinea pig received a single intraperitoneal injection of OVA (0.06 
mg/ml, Sigma St Louis, EU) with aluminium hydroxide (1 mg/ml; J.T. Baker, NJ, EU) 
dispersed in saline solution (Fig. 1). Sensitization was reinforced 8 days later with OVA 
aerosols (3 mg/ml saline) delivered during 5 min. Aerosols were produced by an US-1 
Bennett nebulizer (flow, 2 ml/min), releasing mixed particles, 44% <4 µm in size, 38% of 4-
10 µm, and 18% >10 µm (multistage liquid impinger, Burkard Manufacturing Co., 
Rickmansworth, Hertfordshire, UK). From day 15 onward, guinea pigs were challenged 
every 10 days with OVA aerosols (1 mg/ml in the first challenge, and 0.5 mg/ml in the 
eleven subsequent challenges) during 1 min. Control guinea pigs received inhalatory 
challenges with vehicle (saline solution). All challenges were carried out while the guinea 
pig was inside a barometric plethysmograph, allowing us to record acute 
bronchoobstructive response to the antigenic challenge immediately after OVA delivery was 
ended, as described in the following section. This guinea pig model of allergic asthma does 
not develop a noticeable late airway response. We corroborated that this sensitization 
procedure induces production of OVA-specific IgG1 and IgE. 
2.3 Barometric plethysmography 
Whole-body single-chamber plethysmography for freely moving animals (Buxco Electronics 
Inc., Troy, NY, USA) was used to evaluate the pulmonary function indirectly according to 
principles previously described (Hamelmann et al., 1997; Vargas et al., 2010). Briefly, 
pressure inside the plethysmograph was measured through a differential transducer 
connected to a preamplifier. Because air in lungs is heated and humidified, during the 
inspiratory phase the volume of air inside the thorax is larger than the volume of air drawn 
by the animal from the plethysmographic chamber. This larger volume of air inside the 
thorax produces an increase in the plethysmographic chamber pressure, and the reverse 
occurs during the expiratory phase. The signal from the chamber was processed with 
computer-installed software (Buxco Biosystem XA v1.1) to calculate several respiratory 
parameters, including Penh (enhanced pause). This index was obtained by the following 
formula (Hamelmann et al., 1997) (1):  
 Penh = ((Te-Rt)/Rt)(PEP/PIP) (1) 
where Te = expiratory time (s), Rt = relaxation time (s), PEP = peak expiratory pressure (cm 
H2O), and PIP = peak inspiratory pressure (cm H2O). The software was adjusted to only 
include breaths with a tidal volume of 1 ml or more, with minimal inspiratory time of 0.15 s, 
maximal inspiratory time of 3 s, and maximal difference between inspiratory and expiratory 
volumes of 10%. After the guinea pig was placed inside the plethysmographic chamber, a 5-
min baseline Penh recording was initiated 5 min later. One minute after OVA or vehicle 
administration, Penh was recorded at 5 and 10 min, and every 15 min thereafter. Because 
Penh was calculated for each breath, adjustments were made to the software to average 
values from all breaths occurring during 15 s, and then to average these values during the 
last 5 min of each period. 
www.intechopen.com
 
Inflammatory Diseases – Immunopathology, Clinical and Pharmacological Bases 
 
322 
Saline
Groups
“Asthma model” (n= 6)
Control (n=6)   
“Asthma model”-PtI-collagen (n=6)  
Sham (Control-PtI-collagen) (n=5)
OVA
PtI-collagenx
0 95
Initial immunization
12
8 15 25 35 45 55 65 75 85
Days
1 2 3 4 6 7 8 9 10
Reinforcement
Challenge number
115
105 115
x x x x x x x x x x x x
125
x x x x x x x x x x x x
  
 
Fig. 1. Experimental design. After initial immunization and reinforcement, guinea pigs 
received up to twelve antigen challenges. Animals were sacrificed at days 125 after antigen-
induced airway hyperresponsiveness was evaluated. =antigen-induced airway 
hyperresponsiveness evaluation day, OVA=ovalbumin, PtI-collagen= polymerized type I 
collagen. 
2.4 PtI-collagen treatments 
Some guinea pigs from asthma model group received 0.66 mg/ml PtI-collagen dispersed in 
20 ml of saline for 5 min (n= 5-6). PtI-collagen doses and frequency of administration were 
selected in accordance to a previous study (Moreno-Alvarez et al., 2010). PtI-collagen 
aerosols were administrated with an US-1 Bennett nebulizer at a flow rate of 2 ml/min 
every 5 days from day 65. PtI-collagen was administrated one hour after OVA when it 
coincided with the OVA-challenge day. Five guinea pigs from the control group received 
0.66 mg/ml PtI-collagen to constitute the sham group. 
2.5 Antigen-induced airway responsiveness 
Airway responsiveness was evaluated in all groups at day of sensitisation reinforcement 
and at sixth and twelfth OVA challenges by comparing histamine dose-response curves 
before and after OVA administration. In guinea pig, histamine aerosol administration 
induces an all-or-none response (Fig. 2). To avoid receptor desensitization, we administrated 
non-cumulative doses of histamine from low to high doses (0.01 to 0.1 mg/ml; Fig. 2) after 
an initial Penh baseline acquisition. The dose-response curve was stopped at the first airway 
obstructive response in which usually Penh reached three times its baseline level. Each 
histamine dose was delivered during 1 min, and the average Penh value during the 
following 5 min was obtained. The interval between doses was 10 min. Once Penh had 
returned close to the initial baseline value (<50% increment) (Bazan-Perkins et al., 2004), 
OVA challenge was administered. The second curve was performed 3 h after OVA 
challenge. 
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Fig. 2. Dose-response curve to aerosolized histamine. After initial baseline acquisition (0 
mg/ml histamine), guinea pigs received non-cumulative doses to histamine. The arrow 
shows the provocative dose 200% (PD200), i. e., the interpolated histamine dose that caused a 
three-fold increase of basal Penh. 
2.6 Cell counts in bronchoalveolar lavage 
One hour after concluding the second histamine curve, and when at least 50% of baseline Penh 
was reached (Bazan-Perkins et al., 2004), animals were overdosed with an intraperitoneal 
injection of pentobarbital sodium (65 mg/kg) and the trachea was cannulated. Using a syringe, 
5 ml of saline solution (37°C) was introduced through the tracheal tube and gently recovered 1 
min later. This procedure was repeated and the recovered fluid was mixed with the first 
bronchoalveolar lavage fluid. Total recovered fluid was immediately centrifuged for 10 min at 
500 g (4°C), the cell pellet was resuspended in 1-ml saline solution, and total cells were 
counted employing the Kimura stain in a Neubauer haemocytometer. Volume was adjusted to 
obtain 1 x 106 cells/ml and 50 µl of this mixture was deposited on a slide stainer (7120 
Aerospray, Wescor Inc., Logan, Utah, USA) to be stained with Romanowsky stain for 
differential cell counting. Cell counts were expressed as number of cells per ml of BAL fluid. 
Cell viability >80% was confirmed by Trypan blue exclusion technique in each BAL. All 
smears were coded, and cells were counted in blind fashion. 
2.7 Conventional histology and automated morphometry analysis 
Left caudal lung lobe was dissected and fixed by manually perfusing 10% neutral buffered 
formaldehyde solution via intra-arterial route until lung lobe was exsanguinated. Lung 
fragments obtained by sagittal cutting were embedded in paraffin, and 4 µm-thick lung 
sections were stained with Masson trichrome stain. Surface areas (µm2) of airways 
subepithelial mucosa were determined through the use of automated morphometry (Qwin, 
Leica Microsystems Imaging Solutions, Cambridge, UK). All measurements were conducted 
in six bronchi chosen at random from each animal, data was adjusted by length of the 
corresponding basement membrane, and their average was considered the final result. 
Bronchus was identified by presence or absence of cartilage in airway wall, respectively. 
2.8 Statistical analysis 
Airway responsiveness to histamine was evaluated by means of the provocative dose 200% 
(PD200), i.e., the interpolated histamine dose that caused a three-fold increase of basal Penh. 
Changes in histamine responsiveness induced by antigenic challenge was evaluated by the 
PD200 ratio, i.e., PD200 value observed after OVA challenge divided by PD200 value before 
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challenge (Bazan-Perkins et al., 2009). In multiple comparisons, one way or repeated 
measures ANOVA followed by Tukey or Bonferroni tests were used. Statistical significance 
was set at two-tailed P < 0.05. Data in the text and figures are expressed as mean ± SE. 
3. Results 
Considering that control and sham groups had quite similar results in functional and 
structural analyses, to avoid excessive data, only control group is shown in the result section. 
3.1 Allergen-induced airway obstructive response in PtI-collagen treated guinea pigs 
Saline aerosol challenges in control group did not modify Penh basal values. In asthma 
model guinea pigs, OVA-nebulization at sensitisation reinforcement day did not alter Penh 
baseline. Nevertheless, since first to twelve OVA-challenges, the asthma model guinea pigs 
showed a transient Penh increment and maximum responses in the first hour were 
significantly higher than maximum values in control (P < 0.001; n=6 each group; Fig. 3). PtI-
collagen administration in asthma model guinea pigs did not modify maximal Penh 
responses in comparison with asthma model group but also were higher than control (P < 
0.001; n=6 each group; Fig. 3). 
Baseline Penh values in control animals were similar throughout the study. In asthma model 
group, a progressive baseline Penh increment that reaches statistical differences at the tenth 
to the twelfth OVA-challenges in comparison with control group was observed (P < 0.05; 
n=6 each group; Fig. 4). PtI-collagen treated asthma model guinea pigs also showed a 
similar pattern of baseline Penh increment and a post hoc analysis demonstrated statistically 
significant higher Penh values at the eight, tenth (P < 0.05) and eleventh (P < 0.01) OVA 
challenges in comparison with control group (n=6 each group; Fig. 4). 
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Fig. 3. Airway obstructive responses induced by ovalbumin challenge in PtI-collagen treated 
allergic guinea pigs. Average of maximum airway obstructive responses (Rmax) induced by 
ovalbumin (open squares and circles) and saline (close squares) challenges in guinea pigs.  
PtI-collagen treated guinea pigs are shown in open circles. *P < 0.001 compared with control 
group (repeated measures ANOVA with Bonferroni´s multiple comparisons test). Symbols 
represent the means ± SE of n = 6 of each group. Penh = airway obstruction index. R= 
sensitisation reinforcement day. 
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Fig. 4. Baseline airway obstruction index (Penh) changes in PtI-collagen treated guinea pigs. 
Values of saline (close squares) and ovalbumin (open squares and circle) challenged guinea 
pigs were obtained at the beginning of each plethysmographic recording and before drug 
administration. PtI-collagen treated guinea pigs are shown in open circles. *P < 0.05 asthma 
model compared with control group, +P < 0.05 and ++P < 0.01, PtI-collagen treated guinea 
pigs compared with control groups (repeated measures ANOVA with Bonferroni´s multiple 
comparisons test). Symbols represent the means ± SE of n = 6 of each group. R= sensitisation 
reinforcement day. 
3.2 Airway responsiveness in PtI-collagen treated guinea pigs 
PD200 ratio to aerosolised histamine was similar at the sensitisation reinforcement day in 
control and asthma model groups (Fig. 5). In the sixth OVA challenges, asthma model 
guinea pigs groups exhibited a significant decrease of histamine PD200 ratio in comparison 
with control group (n = 6 each group; P < 0.05; Fig. 5). At twelfth OVA-challenge, asthma 
model guinea pigs showed a significantly PD200 ratio decrement in comparison with control 
(n = 6 each group; P < 0.001) and asthma model guinea pigs treated with PtI-collagen (n = 6 
each group; P < 0.001; Fig. 5). 
3.3 Airway structure in PtI-collagen treated guinea pigs 
Subepithelial mucosa collagen deposit in bronchus, identified with Masson trichrome 
staining, in asthma models groups was significantly higher than control group (P < 0.001 
when comparing control vs. asthma model; P < 0.05 when comparing asthma model PtI-
collagen treated vs. control guinea pigs; n = 6 each group; Fig. 6). In addition, PtI-collagen 
asthma model guinea pigs showed a significantly decrement in comparison with asthma 
model untreated animals (P < 0.001; n = 6; Fig. 6). 
3.4 Airway inflammation in PtI-collagen treated guinea pigs 
Lymphocyte and macrophage numbers in bronchoalveolar lavage fluid were not different 
among groups (data not shown). Eosinophil and neutrophil increased numbers were 
statistically significant in comparison with the control group (P < 0.01; Fig. 7). Likewise, PtI-
collagen treatment significantly reduced neutrophil counts in comparison with non-treated 
PtI-collagen group (P < 0.01; Fig. 7). 
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Fig. 5. Airway responsiveness to histamine before and after OVA challenge in PtI-collagen 
guinea pigs. Symbols correspond to PD200 ratio of control (closed squares) and asthma 
model guinea pigs (open circles and squares) PtI-collagen treated guinea pigs are shown in 
open circles. *P < 0.05 and **P < 0.01 asthma group compared with control; ♯P<0.05 PtI-
collagen group compared with (repeated measures ANOVA with Bonferroni´s multiple 
comparisons test); §P < 0.01 untreated asthma group compared with PtI-collagen treated 
guinea pigs. The line delimited the borderline between hyperresponsiveness (below the line) 
and hyporresponsiveness (over the line). Symbols represent the means ± SE of n = 6 of each 
group. R= sensitisation reinforcement day. 
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Fig. 6. Subepithelial mucosa changes by PtI-collagen treatment in asthma model. Area of 
subepithelial mucosa (SEM) of bronchi adjusted by the basement membrane (BM) perimeter, 
as measured by automated morphometry. Bars and vertical lines are mean ± SE of n = 6 in 
each group. *P < 0.05, **P < 0.01 comparing control; §P < 0.05 when compared untreated 
asthma guinea pigs with PtI-collagen treated asthma model guinea pigs (one way ANOVA 
with Tukey's multiple comparisons test). C = control, AM = untreated asthma model and 
AM + PtI-collagen = asthma model guinea pigs treated with PTI-collagen. 
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Fig. 7. Bronchoalveolar granulocyte infiltration changes by PtI-collagen treatment in asthma 
model. Bars and vertical lines are mean ± SE of n = 6 in each group. *P < 0.05 when 
comparing vs. control, +P < 0.05 when compared untreated asthma guinea pigs with PtI-
collagen treated asthma model guinea pigs (one way ANOVA with Tukey´s multiple 
comparisons test). C = control, AM = untreated asthma model and AM + PtI-collagen = 
asthma model guinea pigs treated with PTI-collagen. 
4. Discussion 
PtI-collagen is a biodrug which has shown immunomodulatory, fibrolytic, haemostatic and 
tissue regeneration properties. In humans, acute and chronic PtI-collagen treatments have 
been shown not to be genotoxic or to induce a localized hypersensitivity reaction, 
fibroproliferation (Krotzsch-Gomez et al., 1998), lymphoproliferation, human antiporcine 
collagen, or anti-collagen–polyvinylpyrrolidone antibodies (Furuzawa-Carballeda et al., 
2003). In addition, PtI-collagen is capable to reduce the inflammatory infiltrate (Furuzawa-
Carballeda et al., 1999; Krotzsch-Gomez et al., 1998), to modulate type I and III collagen 
turnover (Furuzawa-Carballeda et al., 1999; Furuzawa-Carballeda et al., 2005; Furuzawa-
Carballeda et al., 2002; Krotzsch-Gomez et al., 1998), and to downregulate the expression 
level of TNF, interleukin-1┚ (Furuzawa-Carballeda et al., 2005; Furuzawa-Carballeda et al., 
2002; Krotzsch-Gomez et al., 1998), inteleukin-8 (Furuzawa-Carballeda et al., 2002), platelet 
derived growth factor (Furuzawa-Carballeda et al., 2005; Krotzsch-Gomez et al., 1998), 
vascular cellular adhesion molecule-1 (Furuzawa-Carballeda et al., 2005; Furuzawa-
Carballeda et al., 2002), endothelial leukocyte adhesion molecule-1, TGF-┚1 (Furuzawa-
Carballeda et al., 2005; Krotzsch-Gomez et al., 1998) and cyclooxygenase-1 (Furuzawa-
Carballeda et al., 2002). Additionally, tissue inhibitor of metalloproteinase-1 and Fas 
expression as well as apoptosis are upregulated by this biodrug (Furuzawa-Carballeda et al., 
2002). In the current study we have found that PtI-collagen displays anti-inflammatory, anti-
fibrotic and functional properties in a guinea pig asthma model. 
Asthma is an airway inflammatory chronic disease that exhibits heterogeneous and variable 
symptoms derived from airway physiologic abnormalities (Busse & Lemanske, 2001; Faffe, 
2008; Hargreave, In press; Jenkins et al., 2005; Lemanske & Busse, 2010). A typical 
inflammatory response in asthma exacerbation is a transient influx of neutrophils, followed 
by eosinophils accumulation (Fahy, 2009; Taube et al., 2003; Venge, 2010). Airway 
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eosinophilia is an important feature of asthma that has been related to airway remodelling 
(Fahy, 2009; Kariyawasam & Robinson, 2007; Koerner-Rettberg et al., 2008; Macedo et al., 
2009; Passalacqua & Ciprandi, 2008; Venge, 2010). Neutrophilia in asthma has been 
associated to the disease severity (Fahy, 2009; Macedo et al., 2009; Wenzel, 2003). Recently, it 
has been suggested that chronic or unresolved inflammation is the result of the loss of 
balance of protective mechanisms of the immune system or 'Yin' (tumoricidal) and 'Yang' 
(tumorigenic) processes (Khatami, 2008; Khatami, 2009; Khatami, 2011); and a chronic 
allergic process has been shown to facilitate the 'Yang' side of unresolved inflammation 
(Kathami, 2005). In the guinea pig asthma model, PtI-collagen administration during the 
acute phase, i.e. from the third to sixth antigen challenges, prevents the infiltration of 
inflammatory cells and mediators such  as neutrophils and TNF (Moreno-Alvarez et al., 
2010). In the current study we have shown that PtI-collagen administrated after the acute 
phase, i.e. from the sixth to twelfth antigen challenges, is capable to revert the neutrophilic 
inflammation, suggesting that PtI-collagen is able not only to prevent the development of 
inflammation but also to revert this process. 
A consequence of chronic inflammation in the guinea pig asthma model is the accumulation 
of extracellular matrix components (Bazan-Perkins et al., 2009). It is known that extracellular 
matrix accumulation in airways is a central component of remodelling that has been 
detected even in mild childhood asthma (Barbato et al., 2003) and has been associated with 
asthma severity (Chetta et al., 1997; Wenzel, 2003). Extracellular matrix accumulation is a 
phenomenon occurring at the sixth antigen challenge in our asthma model (Moreno-Alvarez 
et al., 2010). In the present study we have observed that PtI-collagen administration, after 
the sixth antigenic challenge, reverts this accumulation, suggesting that PtI-collagen has 
important anti-fibrotic properties in the airway wall.  
The functional consequences of extracellular matrix accumulation include the residual and 
permanent airflow limitation (Bazan-Perkins et al., 2009; Sobonya, 1984). In our guinea pig  
asthma model, a progressive rise in the baseline airway obstruction associated to 
extracellular matrix component accumulation in airway wall has been observed (Bazan-
Perkins et al., 2009). Nevertheless, our current results show that, although PtI-collagen 
reverts the accumulation of extracellular matrix components in the airway wall, the baseline 
airway obstruction rising during the antigenic challenge persists. This suggests that the 
airway wall thickening in the guinea pig asthma model is not involved in the fixed airflow 
limitation, and that PtI-collagen has no effect on baseline airflow limitation. 
A distinctive physiologic abnormality in asthma is airway hyperresponsiveness (Busse, 
2010; Cockcroft et al., 2007; O'Byrne & Inman, 2003; Sugita et al., 2003). Airway 
hyperresponsiveness development has been associated to airway inflammation (Bazan-
Perkins et al., 2009; Busse, 2010; Cockcroft & Davis, 2006; O'Byrne & Inman, 2003; Sugita et 
al., 2003) and remodelling (Cockcroft & Davis, 2006; Cockcroft et al., 2007; O'Byrne & Inman, 
2003). We have previously described in our guinea pig asthma model (Bazan-Perkins et al., 
2009) that the number of neutrophils and eosinophils and the extent of extracellular matrix 
accumulation in airways is related to airway hyperresponsiveness degree. It is noteworthy  
that PtI-collagen treatment is capable to reduce (Moreno-Alvarez et al., 2010) and revert the 
neutrophil and extracellular matrix accumulation in airway. Then, our data suggest that 
neutrophils and fibrosis might be key factors in the development of airway 
hyperresponsivess in asthma model guinea pig. Finally, PtI-collagen did not modify the 
maximal airway obstructive responses, suggesting that the modulation of the allergic 
response is not affected by this biodrug. 
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5. Conclusions 
Our data suggest that PtI-collagen is able to revert the development of neutrophilic 
infiltration, extracellular matrix deposition and airway hyperresponsiveness in a guinea pig 
model of chronic asthma. Additionally, it is likely that neutrophils and extracellular matrix 
component accumulation play significant roles in the development of airway 
hyperresponsivess in the guinea pig asthma model. 
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